Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gene therapy targets rare dementia at its genetic root

NCT ID NCT04408625

First seen Jan 09, 2026 · Last updated May 21, 2026 · Updated 20 times

Summary

This study tests a single-dose gene therapy (LY3884963) in 35 adults with frontotemporal dementia caused by a progranulin gene mutation. The goal is to see if it safely raises progranulin levels in the body and brain, which may slow disease progression. Participants receive one of two doses and are followed for 5 years to monitor safety and effects on thinking and daily function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRONTOTEMPORAL DEMENTIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • AP-HM Hôpital de La Timone

    Saint-Pierre, Marseille, 13386, France

  • Centre Mémoire de Ressources

    Lille, 59000, France

  • Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología

    Barcelona, 08036, Spain

  • Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa

    Donostia / San Sebastian, 20014, Spain

  • Hospital of the University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street

    Philadelphia, Pennsylvania, 19104, United States

  • Lahey Hospital & Medical Center, 41 Burlington Mall Road

    Burlington, Massachusetts, 01805, United States

  • Le Ber, Institut du Cerveau et de la Moelle Epinière

    Paris, 75013, France

  • PPD Phase 1 Clinic, 100 West Gore Street, Suite 202

    Orlando, Florida, 32806, United States

  • Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street

    Camperdown, New South Wales, 2050, Australia

  • UZ Leuven, Neurologie Herestraat 49

    Leuven, 3000, Belgium

  • University College London,Queen Square, Dementia Research Building, London,

    London, WC1N 3BG, United Kingdom

  • k2 Medical Research-Maitland

    Maitland, Florida, 32751-5669, United States

Conditions

Explore the condition pages connected to this study.